Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,217 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Viral Respiratory Infection Clear all

Conditions: Covid19
Interventions: Core Warming, Standard of Care; Device · Other
Lead sponsor: Sharp HealthCare; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
Interventions: Alteplase 50 MG [Activase]; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more

Conditions: COVID 19, Coronavirus
Interventions: Fluvoxamine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Belleville, Illinois • St Louis, Missouri

Conditions: Long COVID, Long Covid19, Long Covid-19
Interventions: Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more

Conditions: Long COVID
Interventions: Acute Placebo Visit, Acute Progressive Carbon Dioxide, Acute Intermittent Hypoxia, Training: Progressive Carbon Dioxide Ramping, Training: Intermittent Hypoxic Exposure, Training: Placebo Control; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: SARS-CoV-2 Infection
Interventions: COVID-HIG; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Springfield, Missouri

Conditions: HCV Infection
Interventions: ACH-0137171; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more

Conditions: Coronavirus Infection, Type 2 Diabetes
Interventions: Linagliptin, Insulin regimen; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Covid19
Interventions: Not listed
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 100 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: SARS-CoV2 Infection
Interventions: General SARS-CoV-2 Communication, Rural-Targeted SARS-CoV-2 Communication; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Influenza -Like Illness, Influenza A, Influenza Type B, Respiratory Viral Infection, Respiratory Tract Infections
Interventions: Not listed
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years and older
Enrollment: 5,233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Mateo, California

Conditions: COVID-19
Interventions: Active Intervention Group; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Covid19
Interventions: C144-LS and C-135-LS; Biological
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: AZD7442, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 50
States / cities: Guntersville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 42 more

Conditions: COVID-19, Diabetes Mellitus, COVID-19 Pneumonia, COVID-19 Respiratory Infection
Interventions: No Intervention; Other
Lead sponsor: Arrowhead Regional Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 589 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Colton, California

Conditions: Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
Interventions: Liraglutide Pen Injector [Saxenda], Medication Diary; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Covid19, Influenza, Pneumonia, Vaccine Refusal
Interventions: Full VEPMP Intervention, Partial VEPMP Intervention, Delayed VEPMP Intervention; Behavioral
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 65 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Post SARS-CoV2 (COVID-19)
Interventions: Tele-exercise; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 5
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 2 more

Conditions: COVID-19
Interventions: Remdesivir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 6 more

Conditions: Viral Vaccines
Interventions: Inactivated influenza vaccine; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Covid19
Interventions: Weight-based dexamethasone dose; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: COVID-19
Interventions: Experimental Group, Placebo Group; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: COVID-19, Myocardial Reperfusion Injury, Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Not listed
Enrollment: 4,695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection

RECOVER-ENERGIZE Platform Protocol

Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

Effects of DPP4 Inhibition on COVID-19

Symptom-Based Markers for COVID-19 Transmission

Rural Tailored COVID-19 Communication to Promote SARS-CoV-2 Antibody Testing in Saliva

Home Testing of Respiratory Illness

Engaging Church Health Ministries to Decrease Coronavirus Disease-19 Vaccine Hesitancy in Underserved Populations

RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

Increasing COVID-19, Influenza, and Pneumonia Vaccine Uptake

Home-Based Exercise Tele-Rehabilitation After COVID-19

Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children

PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US

Flu Vaccine Responses in the Setting of Melanoma Treatment

Randomized Open Investigation Determining Steroid Dose

Atovaquone for Treatment of COVID-19

Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19